Pricing Log in Create free account
Saturday 17 October 2026 Export CDNA’s income statement to Excel — free account

CareDx, Inc.

CDNA Healthcare Diagnostics & Research

CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 52.2%, EPS grew 1,443.8% and free cash flow grew 223.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

63.81 2.87 −4.30%
Market cap
$3.5B
P/E
29.7×
Fwd P/E
2,967×
Dividend yield
—
F-score
5/9
Altman Z
4.14
Beneish M
−3.36
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 13.31
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 2 1 — 1 2 5 2 4 — —
Insider Ownership 8.51%

Capital & Financial Ratios $m

Market Cap 3,450.00
Revenue 458.09
Net Income 111.01
Free Cash Flow 84.71
Net Debt (373.64)
Current Ratio 4.58 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 29.68
Fwd P/E 2,967.00 (above 35: high)
P/S ratio 7.17
P/B ratio 7.72 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 106.51% (at or above 15%: strong)
Next Y EPS Growth 7.69%
Next Y revenue growth 30.36% (at or above 10%: strong)
Next 5Y EPS Growth 46.93% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.4×, against a ten-year median of 2.9×; over the ten years it ranged from 0.1× in 2023 to 18.1× in 2018.
P/S against its own 10 years 67.12%
10-year low 10-year high
P/B against its own 10 years 69.33%
10-year low 10-year high
EV/Sales against its own 10 years 66.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 235 261 177 374
Receivables 51 65 43 34
Inventory 19 20 27 7
Other — — — —
314 352 257 429
2023 2024 2025 Q'26
Payables 13 8 10 9
ST’ Debt — — — —
Other — — — —
78 89 90 94

Compound Annual Growth %

10y 5y 3y
Sales 29.72% 14.59% 5.68%
Cash Flow 0.00% 4.69% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 26.24% 1.77% (11.07%)

Revenue $m

Mar Jun Sep Dec Year
’26 118 132 — — —
’25 85 87 100 108 380
’24 72 92 83 87 334
’23 77 70 67 66 280
’22 79 81 79 82 322
’21 67 74 76 79 296
’20 38 42 53 59 192
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 4 31 — — —
’25 (27) 10 37 21 42
’24 (15) 19 13 22 38
’23 1 0 (10) (8) (18)
’22 (21) (4) (7) 7 (25)
’21 (34) 10 0 4 (19)
’20 (3) 24 5 7 33
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 29 — — —
’25 (28) 9 35 19 35
’24 (17) 17 11 20 32
’23 (2) (3) (13) (10) (28)
’22 (30) (11) (13) 4 (50)
’21 (36) 1 (3) (2) (40)
’20 (5) 20 1 7 23
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.05 2.07 — — —
’25 (0.19) (0.16) 0.03 (0.08) (0.40)
’24 (0.32) (0.09) (0.20) 1.51 0.93
’23 (0.44) (0.46) (0.43) (2.21) (3.54)
’22 (0.37) (0.41) (0.32) (0.34) (1.44)
’21 (0.01) (0.04) (0.23) (0.31) (0.59)
’20 (0.14) (0.15) (0.06) (0.07) (0.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 2.50 0.76 4.92 18.75 13.04 39.16 10.68 4.80 7.42 10.96

Analyst estimates 2026–2028

Powerpack
High 6.84 7.98 30.80 41.27 79.92 99.83 47.82 18.04 34.84 25.95
People
People Employees 161 179 231 386 475 645 738 643 650 765
Revenue/emp, $m 0.25 0.27 0.33 0.33 0.40 0.46 0.44 0.44 0.51 0.50
Income, $m
Income, $m Revenue 41 48 77 127 192 296 322 280 334 380
Gross margin, % 48.02 55.78 56.92 64.23 67.16 67.14 65.13 63.59 67.14 67.55
EBT (41) (57) (48) (24) (20) (32) (76) (190) 53 (21)
EBT margin, % (101.80) (118.51) (62.97) (18.85) (10.28) (10.83) (23.69) (67.83) 15.84 (5.55)
Net income (40) (56) (47) (22) (19) (31) (77) (190) 53 (21)
Depreciation 7 8 7 7 10 13 16 15 20 22
Per share, $
Per share, $ Revenue 2.46 2.07 2.15 3.01 4.13 5.67 6.03 5.21 6.32 7.13
Earnings (2.39) (2.38) (1.31) (0.52) (0.40) (0.59) (1.44) (3.54) 1.00 (0.40)
Cash flow (1.00) (0.61) (0.11) (0.07) 0.72 (0.37) (0.47) (0.34) 0.72 0.79
Capex (0.03) (0.01) (0.20) (0.08) (0.22) (0.39) (0.46) (0.17) (0.12) (0.12)
Free cash flow (1.03) (0.62) (0.32) (0.15) 0.50 (0.76) (0.93) (0.51) 0.60 0.67
Book value 1.20 (0.26) 2.69 2.35 5.97 8.92 8.08 4.86 7.17 5.69
Shares, m 16 23 36 42 46 52 53 54 53 53
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.19 0.00
P/S 0.93 3.40 11.70 7.16 17.52 8.02 1.84 2.29 3.39 2.64
P/B 1.92 0.00 9.34 9.18 12.13 5.10 1.37 2.46 2.99 3.31
EV/Sales 1.10 3.76 11.04 6.86 16.44 6.85 0.94 1.46 2.61 2.18
EV/FCF (2.61) (12.53) (139.89) (120.34) 144.12 (51.32) (6.08) (14.29) 29.38 24.00
Cash, $m
Cash, $m Operating cash flow (17) (14) (4) (3) 33 (19) (25) (18) 38 42
Capex (1) 0 (7) (3) (10) (20) (24) (9) (6) (7)
Free cash flow (17) (14) (11) (6) 23 (40) (50) (28) 32 35
Balance, $m
Balance, $m Working capital (14) (16) 62 37 204 356 312 236 262 167
Total debt 24 34 0 3 18 21 39 — — —
Net debt 7 17 (65) (38) (225) (348) (293) (235) (261) (177)
Shareholders’ equity 20 (6) 96 99 278 466 431 261 378 303
Returns, %
Returns, % ROA (59.64) (69.21) (43.64) (15.56) (7.19) (6.56) (13.81) (37.69) 10.97 (4.72)
ROIC (88.22) (113.15) (31.09) (25.23) (26.58) (15.83) (35.02) (490.55) 21.63 (15.28)
ROE (160.26) (803.49) (103.93) (22.54) (9.94) (8.25) (17.09) (54.98) 16.43 (6.27)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

CareDx, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GRAL GRAIL, Inc. $6.1B — (loss-making) — (loss-making) +25.72% (above 0%: growing) n/m −4.95% (below 0%: shrinking) (28.12%) (388.89%) Compare
RDNT RadNet, Inc. $5.5B — (loss-making) 279× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
SHC Sotera Health Company $5.2B 31.4× 23.7× +9.18% (above 0%: growing) +533.33% (above 0%: growing) +60.56% (above 0%: growing) 55.38% 33.23% Compare
BLLN BillionToOne, Inc. $4.9B 95.0× 99.4× +64.40% (above 0%: growing) n/m +400.65% (above 0%: growing) 70.45% 5.03% Compare
ADPT Adaptive Biotechnologies Corporation $4.1B — (loss-making) — (loss-making) +21.53% (above 0%: growing) n/m +42.04% (above 0%: growing) 71.82% (22.04%) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29% Compare
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81%
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%) Compare
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
Median of peers $4.5B 31.4× 72.3× +18.51% — +14.00% 61.87% 0.09%

All 52 Diagnostics & Research stocks →

CareDx, Inc. (CDNA) key facts

  • Strength: CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
  • CareDx, Inc. (CDNA) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CDNA traded at $63.81, a market capitalization of $3.5 billion.
  • Return on equity was −6.27% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.14 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

CareDx, Inc. (CDNA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CDNA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com